What are the recommended screening guidelines for women throughout the lifespan in Canada?

Screening Guidelines for Women Across the Lifespan in Canada

Cervical Cancer Screening

Women should begin cervical cancer screening at age 21 and continue until age 65, with the specific strategy depending on age and prior screening adequacy. 1

Ages 21-29 Years

• Screen with cytology (Pap test) alone every 3 years 1
• Do not use HPV testing as a primary screening method in this age group due to high prevalence of transient HPV infections that resolve spontaneously 1

Ages 30-65 Years

• Preferred strategy: HPV testing with cytology triage every 5 years 1
• Acceptable alternatives: Cytology alone every 3 years, or HPV and cytology co-testing every 5 years 1
• HPV-based strategies detect more high-grade precancerous lesions (CIN 3+) earlier compared to cytology alone, though this comes with increased referrals to colposcopy 1

Stopping Screening After Age 65

• Women may stop screening at age 65 only if they have adequate prior screening documentation 2
• Adequate screening is defined as: (a) three consecutive negative cytology tests within 10 years with the most recent ≤5 years ago, OR (b) two consecutive negative HPV + cytology co-tests within 10 years with the most recent ≤5 years ago, OR (c) two consecutive negative primary HPV tests within 10 years with the most recent ≤5 years ago 2
• Women over 65 with inadequate or no prior screening must continue screening until adequate negative screening is documented 2
• 29-42% of cervical cancer cases in older women occur in those who were never screened 2

Special Circumstances

• After any high-grade precancerous lesion (CIN 2, CIN 3, or adenocarcinoma in situ), continue screening for at least 20 years, even if this extends beyond age 65 2
• Do not resume screening in women who have already met adequate criteria, even with a new sexual partner 2

---

Breast Cancer Screening

Canadian guidelines recommend a risk assessment-first approach for breast cancer screening, with recommendations varying significantly by age. 3, 4

Ages 40-49 Years

• Screening mammography in this age group reduces breast cancer mortality by approximately 0.27 fewer deaths per 1,000 women over 10 years based on randomized controlled trial data 3
• Observational data suggest potentially larger benefits (0.79-0.94 fewer deaths per 1,000 over 10 years) 3
• The decision to screen should involve shared decision-making, weighing the modest mortality benefit against potential harms including false positives and overdiagnosis 3
• Overdiagnosis rates are approximately 1.95 more invasive and in situ cancers per 1,000 screened, or 1 more invasive cancer per 1,000 3

Ages 50-59 Years

• Screening mammography reduces breast cancer mortality by approximately 0.50 fewer deaths per 1,000 women over 10 years (RCT data) 3
• Observational data suggest 1.45-1.72 fewer deaths per 1,000 over 10 years 3
• Overdiagnosis rates are approximately 1.93 more invasive and in situ cancers per 1,000, or 1.18 more invasive cancers per 1,000 3

Ages 60-69 Years

• Screening mammography reduces breast cancer mortality by approximately 0.65 fewer deaths per 1,000 women over 10 years (RCT data) 3
• Observational data suggest 1.89-2.24 fewer deaths per 1,000 over 10 years 3
• The benefit-to-harm ratio becomes more favorable in this age group 3

Ages 70-74 Years

• Screening mammography reduces breast cancer mortality by approximately 0.92 fewer deaths per 1,000 women over 10 years (RCT data) 3
• Observational data suggest 2.68-3.17 fewer deaths per 1,000 over 10 years 3
• Continue screening as long as overall health is good and life expectancy exceeds 10 years 5

Important Caveats

• The overall certainty of evidence for breast cancer screening remains low or very low across all age groups 3
• Screening mammography has been shown to reduce breast cancer mortality by 41% in screened women ages 40-69 years in some analyses 6
• Provincial guidelines vary across Canada, and clinicians should be aware of local recommendations 6

---

Osteoporosis/Fragility Fracture Screening

Women aged 65 years and older should undergo risk assessment-first screening for fragility fracture prevention using the Canadian FRAX tool without bone mineral density. 4

Women Aged 65 Years and Older

• Initial step: Apply the Canadian clinical Fracture Risk Assessment Tool (FRAX) without bone mineral density (BMD) 4
• Use the FRAX result to facilitate shared decision-making about possible benefits and harms of preventive pharmacotherapy 4
• If preventive pharmacotherapy is being considered after discussion: Request BMD measurement using dual-energy x-ray absorptiometry (DXA) of the femoral neck, then re-estimate fracture risk by adding the BMD T-score into FRAX 4
• This is a conditional recommendation based on low-certainty evidence 4

Women Aged 40-64 Years

• Do not screen for fragility fracture prevention (strong recommendation, very low-certainty evidence) 4
• Clinicians should remain alert to changes in health that may indicate the patient has experienced or is at higher risk of fragility fracture 4

---

Colorectal Cancer Screening

While specific Canadian colorectal cancer screening guidelines were not detailed in the provided evidence, U.S. guidelines recommend screening beginning at age 50 for average-risk individuals. 5

• Screening typically begins at age 50 for average-risk populations 5
• Canadian practices generally align with international standards for colorectal cancer screening 7

---

Key Implementation Strategies

For Under-Screened or Never-Screened Women

• Written contact interventions increase screening rates by 619 more per 10,000 (moderate to high certainty) 1
• Personal contact interventions increase screening rates by 797 more per 10,000 (moderate to high certainty) 1
• Universal mail-out of HPV self-sampling kits for cervical cancer screening increases uptake by 1,534 more per 10,000 (moderate to high certainty) 1
• Opt-in HPV self-sampling kits increase screening rates by 727 more per 10,000 (moderate to high certainty) 1

Common Pitfalls to Avoid

• Do not stop cervical cancer screening at age 65 without confirming adequate prior screening documentation 2
• Do not underestimate screening needs in immigrant women from countries without organized screening programs 2
• Do not apply average-risk screening recommendations to high-risk populations (HIV-positive, immunocompromised, prior high-grade lesions, family history of hereditary cancer syndromes) 2, 8
• Be aware that most screening evidence predates widespread HPV vaccination, and future screening strategies may need adjustment 1